Patent · US Active

Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

US12157891B2 · kind B2 · utility

0Cited by

1References

9Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Sahar Gelfman · Tarrytown, US
Ann Ligocki · Tarrytown, US
Giovanni Coppola · Tarrytown, US
Aris Baras · Tarrytown, US
Arden Moscati · Tarrytown, US
Eli A. Stahl · Tarrytown, US
Carmelo Romano · Tarrytown, US
Santiago Mendez Huergo · Tarrytown, US
Jonathan Weyne · Tarrytown, US
Tave Van Zyl · Tarrytown, US

Key dates

Filing date	Oct 13, 2022
Grant date	Dec 3, 2024
Priority date	—
Expiry date	Oct 13, 2042

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/96425
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.